Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic primidone

Executive Summary

Letter to the May 5 Journal of the American Medical Association from FDA's Stuart Nightingale, Peter Rheinstein and James Morrison says agency concludes "no bioequivalence problem with the generic product could be confirmed." The FDA letter responds to Sept. 4, 1987 article entitled "Increased Seizure Frequency with Generic Primidone," which detailed poor response of one patient who had been switched from Wyeth-Ayerst's Mysoline to the generic. An accompanying letter from Bolar points out that Cleveland Clinic incident "clearly indicated that there was no evidence of generic failure since this patient responded poorly" to both versions of the drug," and notes that Bolar sales of product were negatively impacted by article.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS015543

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel